CSBR - Champions Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.28
-0.04 (-0.63%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.32
Open6.26
Bid6.24 x 1000
Ask7.15 x 1000
Day's Range6.03 - 6.28
52 Week Range5.07 - 15.45
Volume4,601
Avg. Volume34,075
Market Cap72.97M
Beta (3Y Monthly)2.52
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • ACCESSWIRE

    Champions Oncology Reports Quarterly Revenue of $6.7 Million

    HACKENSACK, NJ / ACCESSWIRE / September 16, 2019 / Champions Oncology, Inc. (NASDAQ:CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development ...

  • ACCESSWIRE

    Champions Oncology, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / September 16, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR ) will be discussing their earnings results in their 2020 First Quarter Earnings to be held on September 16, 2019 ...

  • ACCESSWIRE

    Champions Oncology to Announce First Quarter Financial Results on Monday, September 16, 2019

    HACKENSACK, NJ / ACCESSWIRE / September 9, 2019 / Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2019, on Monday, September 16, 2019, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EDT (1:30 p.m. PDT). A replay of the call will be available by dialing 877-481-4010 and entering Passcode:53656, or by accessing the Investor tab of the company's website within 72 hours.

  • ACCESSWIRE

    Champions Oncology Reports Record Quarterly Revenue of $7.7 Million For The Fourth Quarter Ended April 30, 2019

    Record Annual Revenue of $27 Million HACKENSACK, NJ / ACCESSWIRE / July 15, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in the development of advanced technology solutions and services to personalize ...

  • ACCESSWIRE

    Champions Oncology to Announce Fourth Quarter Financial Results on Monday, July 15, 2019

    HACKENSACK, NJ / ACCESSWIRE / July 12, 2019 / Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter ended April 30, 2019, on Monday, July 15, 2019, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EST (1:30 p.m. PST). A replay of the call will be available by dialing 877-481-4010 and entering Passcode: 50412, or by accessing the Investor tab of the company's website within 72 hours.

  • ACCESSWIRE

    Champions Oncology Partners with TransCure bioServices to Expand European Business and Operations

    HACKENSACK, NJ / ACCESSWIRE / May 30, 2019 / Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced they have partnered with TransCure bioServices to expand the pharmacology operations of Champions' translational oncology tools throughout Europe. Champions' European customers can continue their unique and consultative interactions with the Champions business development and project leadership teams, along with the option of performing the pharmacology work locally. An operations solution in Europe reduces the intercontinental logistics involved with performing the work in the US.

  • ACCESSWIRE

    Champions Oncology Reports Quarterly Revenue of $6.4 Million

    Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019 HACKENSACK, NJ / ACCESSWIRE / March 18, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of ...

  • ACCESSWIRE

    Champions Oncology to Announce Third Quarter Financial Results on Monday, March 18, 2019

    HACKENSACK, NJ / ACCESSWIRE / March 6, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development ...

  • ACCESSWIRE

    Champions Oncology Participates in Pre-Clinical Studies to Identify Novel Therapy for Childhood Cancer

    HACKENSACK, NJ / ACCESSWIRE / December 17, 2018 / Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced, in partnership with Drs. Narendra Bharathy and Charles Keller at the Children's Cancer Therapy Development Institute (cc-TDI), the publication of in-vivo oncology pharmacology data presenting the effectiveness of the investigational drug entinostat in Patient Derived Xenograft (PDX) models of Pediatric Rhabdomyosarcoma. The data, published in Science Signaling (http://stke.sciencemag.org/content/11/557/eaau7632.editor-summary) demonstrates the advantages of utilizing well-selected PDX models in pre-clinical drug development and helped confirm the earlier research performed by Drs. Bharathy and Keller at cc-TDI.

  • PR Newswire

    Champions Oncology to Announce Second Quarter Financial Results on Monday, December 17, 2018

    HACKENSACK, N.J., Dec. 10, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the second quarter ended October 31, 2018, on Monday, December 17, 2018. The company will host a conference call to discuss the second quarter results that day at 4:30 p.m. EST (1:30 p.m. PST). A replay of the call will be available by dialing 877-481-4010 or 919-882-2331 and entering Passcode: 41544, or by accessing the Investor tab of the company's website within 72 hours.

  • GlobeNewswire

    Analysis: Positioning to Benefit within Red Lion Hotels, P.A.M. Transportation Services, Champions Oncology, Kingstone Companies, Applied DNA Sciences, and Innodata — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswire

    Champions Oncology to Participate in the 9th Annual Craig-Hallum Alpha Select Conference

    HACKENSACK, N.J., Nov. 7, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced that management, will participate in the 9th annual Craig-Hallum Alpha Select conference on Thursday, November 15, 2018, in New York. For more information about the conference or to schedule a one-on-one meeting with management, please contact your Craig Hallum representative or Hayden IR at james@haydenir.com. Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.